Xlife Sciences AG (XSWX:XLS) LT-Debt-to-Total-Asset: 0.10 (As of Dec. 2025)

What is Xlife Sciences AG LT-Debt-to-Total-Asset?

Xlife Sciences AG XSWX:XLS 53 LT-Debt-to-Total-Asset is 0.10 as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 53/100 and a GF Value™ of CHF7.29 (Significantly Overvalued). The stock has 10 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Xlife Sciences AG's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.10.

Xlife Sciences AG's long-term debt to total assets ratio increased from Dec. 2024 (0.10) to Dec. 2025 (0.10). It may suggest that Xlife Sciences AG is progressively becoming more dependent on debt to grow their business.

Xlife Sciences AG (XSWX:XLS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Xlife Sciences AG LT-Debt-to-Total-Asset Related Terms

Xlife Sciences AG LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG LT-Debt-to-Total-Asset Chart

Xlife Sciences AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.13

0.12

0.11

0.10

Xlife Sciences AG Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial										0.11	0.10	0.10	0.10	0.10

53GF Score

Xlife Sciences AG XSWX:XLS

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Xlife Sciences AG LT-Debt-to-Total-Asset Calculation

Xlife Sciences AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	53.366	/	517.117
	=	0.10

Xlife Sciences AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	53.366	/	517.117
	=	0.10

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.10 mean?

Xlife Sciences AG (XSWX:XLS) has a LT-Debt-to-Total-Asset of 0.10 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Xlife Sciences AG and its competitors.

Is Xlife Sciences AG's LT-Debt-to-Total-Asset too high?

Xlife Sciences AG's current LT-Debt-to-Total-Asset is 0.10. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Xlife Sciences AG's LT-Debt-to-Total-Asset compare to VRTX and REGN?

Xlife Sciences AG's LT-Debt-to-Total-Asset of 0.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current LT-Debt-to-Total-Asset is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Xlife Sciences AG stock overvalued right now?

Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.29, compared to a current price of CHF20.20 — trading 177.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.10. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current LT-Debt-to-Total-Asset is 0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF20.20 is trading 177.1% above its estimated GF Value™ of CHF7.29. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

LT-Debt-to-Total-Asset: 0.10
GF Value™: CHF7.29 vs. price of CHF20.20 (177.1% above fair value)
GF Score™: 53/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Industry Healthcare Biotechnology

Comparable Companies XSWX:MOLN XSWX:BIOV XSWX:MMTX XSWX:ADXN XSWX:SANN XSWX:NWRN VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA XKRX:068270 RPRX ROIV BNTX

Other Exchanges XLSz:UK XLS:Germany

Address Talacker 35, Zurich, CHE, 8001

Website https://www.xlifesciences.ch

Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.

53GF Score

Get the complete analysis for XSWX:XLS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF20.20

Price

CHF7.29

GF Value

View XSWX:XLS Analysis

See LT-Debt-to-Total-Asset data for all stocks →